Dr Pardee speaks with ecancertv at ASH 2016 about CPI-613, a novel agent which inhibits the citric acid cycle (TCA).
He describes how blocking metabolic pathways with CPI-613 starves leukaemia cells of energy and reduces treatment resistance, especially when combined with cytarabine (ara-c) for older patients with relapse acute myeloid leukaemia.
Dr Pardee summarises RNA-seq analysis of patient bone marrow as highlighting a possible gene signature of best responders.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.